Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | -- |
| Cost of Revenue | -- | -- | 0.00 | -- | -- |
| Gross Profit | -- | -- | 0.00 | -- | -- |
| SG&A Expenses | 2.77M | 2.07M | 3.68M | 1.27M | 1.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.77M | 3.66M | 5.67M | 2.43M | 2.49M |
| Operating Income | -2.77M | -3.66M | -5.67M | -2.43M | -2.49M |
| Income Before Tax | 101.59M | 49.44M | 9.80M | 59.45M | 13.13M |
| Income Tax Expenses | 23.43M | 11.13M | -212.00K | 11.06M | -126.00K |
| Earnings from Continuing Operations | 78.16M | 38.31M | 10.01M | 48.39M | 13.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 6.00K | 28.00K |
| Net Income | 78.16M | 38.31M | 10.01M | 48.40M | 13.29M |
| EBIT | -2.77M | -3.66M | -5.67M | -2.43M | -2.49M |
| EBITDA | -2.74M | -3.63M | -5.64M | -2.40M | -2.46M |
| EPS Basic | 1.90 | 0.94 | 0.22 | 1.16 | 0.32 |
| Normalized Basic EPS | -0.03 | 0.07 | -0.09 | -0.02 | -0.02 |
| EPS Diluted | 1.84 | 0.91 | 0.22 | 1.13 | 0.31 |
| Normalized Diluted EPS | -0.03 | 0.07 | -0.09 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 41.04M | 40.77M | 40.90M | 41.76M | 41.74M |
| Average Diluted Shares Outstanding | 42.50M | 41.97M | 40.90M | 42.77M | 42.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.10% | 27.05% | -- | -- | -- |